glp-1 and dual glp-1/gip receptor agonists The Sustained Effects of a GIP/GLP-1 Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Frontiers | GLP−1 receptor agonists

Current treatment options for PACS still primarily emphasize managing the symptoms but neglect the underlying cause, such as persistent inflammation, immune dysfunction, and tissue damage

Benefits: Chronic illness or infections Oxidative stress Antioxidant Cell / tissue repair & regeneration Immune system support *Some blood testing may be required

A precision drug delivery approach for CKD using phyto-nanoformulation is given in Fig

Abstract Acute renal failure (ARF) is a sudden, significant, and often reversible decline in kidney function, with 25% of all hospital-administered pharmaceuticals potentially causing nephrotoxicity